Ophthalmic steroid approved for post-op inflammation, pain

FDA has approved Clobetasol Propionate Ophthalmic Suspension 0.05% for the treatment of postoperative inflammation and pain following ocular surgery. Approval was based on data from two randomized, double-masked, vehicle-controlled phase 3 trials that evaluated efficacy and safety of the drug in patients with ≥10 cells in the anterior chamber after cataract surgery.